Cargando…
Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)i...
Autores principales: | Krajewski, Wojciech, Moschini, Marco, Nowak, Łukasz, Poletajew, Sławomir, Tukiendorf, Andrzej, Afferi, Luca, Teoh, Jeremy, Muilwijk, Tim, Joniau, Steven, Tafuri, Alessandro, Antonelli, Alessandro, Gozzo, Alessandra, Mari, Andrea, Di Trapani, Ettore, Hendricksen, Kees, Alvarez-Maestro, Mario, Serrano, Andrea Rodriguez, Simone, Giuseppe, Zamboni, Stefania, Simeone, Claudio, Marconi, Maria Cristina, Mastroianni, Riccardo, Ploussard, Guillaume, Rajwa, Paweł, Laukhtina, Ekaterina, Zdrojowy-Wełna, Aleksandra, Kołodziej, Anna, Paradysz, Andrzej, Tully, Karl, Krajewska, Joanna, Piszczek, Radosław, Xylinas, Evanguelos, Zdrojowy, Romuald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/ https://www.ncbi.nlm.nih.gov/pubmed/33076249 http://dx.doi.org/10.3390/jcm9103306 |
Ejemplares similares
-
Systematic review and meta-analysis on bipolar versus monopolar transurethral resection of bladder tumors
por: Krajewski, Wojciech, et al.
Publicado: (2021) -
Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes
por: Krajewski, Wojciech, et al.
Publicado: (2020) -
Assessment of the oncological outcomes of three different bacillus Calmette–Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer
por: Nowak, Łukasz, et al.
Publicado: (2021) -
Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy
por: Piszczek, Radosław, et al.
Publicado: (2020) -
Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
por: KRAJEWSKI, WOJCIECH, et al.
Publicado: (2020)